XML 45 R33.htm IDEA: XBRL DOCUMENT v3.25.1

Segment Information (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Reportable Segment Information

Reportable segment information was as follows:

			Three Months Ended March 31, 2025
			Taste						Food Ingredients						Health & Biosciences						Scent						Pharma Solutions						Total
Net sales			$	627					$	796					$	540					$	614					$	266					$	2,843
Cost of sales			(377)						(609)						(298)						(344)						(180)
Research & development expenses			(40)						(12)						(52)						(55)						(5)
Selling & administrative expenses			(94)						(92)						(81)						(86)						(32)
Depreciation expense add-back (a)			15						28						29						15						5
Adjusted Operating EBITDA			$	131					$	111					$	138					$	144					$	54					$	578

Reconciliation of Adjusted Operating EBITDA:
Total Adjusted Operating EBITDA												$	578
Depreciation & Amortization												(236)
Interest Expense												(71)
Other Expense, net (b)												(20)
Restructuring and Other Charges (c)												(17)
Impairment of Goodwill (d)												(1,153)
Divestiture and Integration Costs (e)												(51)
Strategic Initiative Costs (f)												(8)
Regulatory Costs (g)												(11)
Other (h)												(5)
(Loss) Income Before Taxes												$	(994)

			Three Months Ended March 31, 2024
			Taste						Food Ingredients						Health & Biosciences						Scent						Pharma Solutions						Total
Net sales			$	619					$	856					$	529					$	645					$	250					$	2,899
Cost of sales			(384)						(673)						(286)						(350)						(181)
Research & development expenses			(39)						(20)						(46)						(55)						(6)
Selling & administrative expenses			(96)						(90)						(88)						(88)						(28)
Depreciation expense add-back (a)			17						35						29						16						12
Adjusted Operating EBITDA			$	117					$	108					$	138					$	168					$	47					$	578

Reconciliation of Adjusted Operating EBITDA:
Total Adjusted Operating EBITDA												$	578
Depreciation & Amortization												(278)
Interest Expense												(83)
Other Expense, net (b)												(1)
Restructuring and Other Charges (c)												(3)
Divestiture and Integration Costs (e)												(58)
Strategic Initiatives Costs (f)												(4)
Regulatory Costs (g)												(35)
Other (h)												(1)
Income Before Taxes												$	115

_______________________

(a)

There is depreciation recorded within cost of sales, research & development expenses, and selling & administrative expenses, so there is an add-back of depreciation to calculate segment Adjusted Operating EBITDA. This reflects how the CODM reviews Segment results.

(b)

Please refer to Note 8 for additional information.

(c)

For 2025, represents costs related to severance as part of the IFF Productivity Program. For 2024, represents costs related to lease impairment and severance as part of the Company's restructuring efforts.

(d)

For 2025, represents the impairment of goodwill related to the Food Ingredients reporting unit.

(e)

For 2025 and 2024, primarily represents costs related to the Company’s planned divestitures. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts. For the three months ended March 31, 2025, there were approximately $51 million of divestiture costs. For the three months ended March 31, 2024, business divestiture and integration costs were approximately $56 million and $2 million, respectively.

(f)

For 2025 and 2024, primarily represents costs related to the Company’s strategic assessment and business portfolio optimization efforts and reorganizing the Global Shared Services Centers, primarily consulting fees, and strategic initiatives related to the Company’s business unit re-organization efforts.

(g)

For 2025 and 2024, represents costs primarily related to legal fees incurred and provisions recognized for the ongoing investigations of the fragrance business.

(h)

For 2025, represents the net impact of costs related to severance, including accelerated stock compensation expense, for certain executives who have separated from the Company. For 2024, represents costs related to the Company’s entity realignment project to optimize the structure of holding companies, primarily consulting fees.

Segment capital expenditures consisted as follows:

			Three Months Ended March 31,
(DOLLARS IN MILLIONS)			2025						2024
Taste			$	27					$	12
Food Ingredients			60						47
Health and Biosciences			40						16
Scent			24						15
Pharma Solutions			28						28
Consolidated			$	179					$	118

Net Sales by Destination of Product Delivery

Net sales, which are attributed to individual regions based upon the destination of product delivery, were as follows:

			Three Months Ended March 31,
(DOLLARS IN MILLIONS)			2025						2024
Europe, Africa and Middle East			$	952					$	977
Greater Asia			670						682
North America			868						866
Latin America			353						374
Consolidated			$	2,843					$	2,899

			Three Months Ended March 31,
(DOLLARS IN MILLIONS)			2025						2024
Net sales related to the U.S.			$	801					$	811
Net sales attributed to all foreign countries			2,042						2,088

X

- Definition

Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

Name:	us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration